A Life-threatening Post-transfusion Reaction in an Individual With Sickle Cell Disease
Note: Please review ASH’s disclaimer regarding the use of the information contained in these articles.
A 57-year-old African American woman living with sickle cell disease (SCD; SS genotype) and baseline hemoglobin (Hgb) of 6.0 to 7.0 g/dL, presented to the emergency department (ED) with shortness of breath and pain consistent with a vaso-occlusive crisis. Her Hgb level was 6.3 g/dL; she was treated with supportive measures and received one unit of phenotypically matched packed red blood cell (PRBC) transfusion for symptomatic anemia. She showed improvements and was subsequently discharged.
She returned to the hospital eight days later with progressive fatigue, decreased oral intake, and dark urine. Initial evaluation revealed tachycardia (heart rate, 110/min), and physical examination was notable for scleral icterus. The rest of the physical exam was unremarkable.
Initial laboratory findings showed the following:
| Test | Result | Range |
| Hgb | 2.8 g/dL | 12-15 g/dL |
| Hematocrit | 8.3% | 36-46% |
| RBC count | 0.87 M/µL | 4.15-5.55 M/µL |
| Mean corpuscular volume | 95.5 fL | 80-100 fL |
| White blood cell count | 28.4 K/µL | 3.8-10.6 K/µL |
| Platelet count | 125 K/µL | 150-450 K/µL |
| Haptoglobin | < 30 mg/dL | 30-200 mg/dL |
| Lactate dehydrogenase | 3,420 IU/L | < 250 IU/L |
| Ferritin | 1,211 ng/mL | 11-307 ng/mL |
| Total bilirubin | 2.7 mg/dL | < 1.2 mg/dL |
| Direct bilirubin | 0.6 mg/dL | 0-0.3 mg/dL |
| Reticulocyte count | 3.5% | 0.5-1.5% |
| Fibrinogen | 263 mg/dL | 200-450 mg/dL |
| D-dimer | > 20 µg/mL | < 0.50 µg/mL |
| Prothrombin time | 19.8 seconds | 11.5-14.5 seconds |
| Activated partial thromboplastin time | 32 seconds | 22-36 seconds |
| Antibody screen | Negative | |
| Direct antiglobulin test | Negative | |
| High sensitivity Troponin | 650 ng/L | < 19 ng/L |
- Gardner K, Hoppe C, Mijovic A, et al. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170:745-756.
- Chadebech P, Habibi A, Nzouakou N, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49:1785-1792.
- Coleman S, Westhoff CM, Friedman DF, et al. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions. Transfusion. 2019;59:2282-2291.
Drs. Sweidan, Vuyyala, Otrock, and Dabak indicated no relevant conflicts of interest.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission